Rigel Pharmaceutical Inc. buy tamam
Start price
18.04.17
/
50%
€2.93
Target price
22.05.17
€3.61
Performance (%)
-21.85%
End price
22.05.17
€2.29
Summary
This prediction ended on 22.05.17 with a price of €2.29. The prediction for Rigel Pharmaceutical Inc. disappointed with a performance of -21.85%. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Rigel Pharmaceutical Inc. | -6.794% | -6.794% | -26.404% | -71.223% |
iShares Core DAX® | -0.051% | 4.829% | 17.062% | 18.811% |
iShares Nasdaq 100 | 1.659% | 2.417% | 38.705% | 56.555% |
iShares Nikkei 225® | 0.658% | -2.173% | 13.159% | 7.768% |
iShares S&P 500 | 0.964% | 2.547% | 30.492% | 47.355% |
Comments by tamam for this prediction
In the thread Rigel Pharmaceutical Inc. diskutieren
Rigel Pharmaceuticals (NASDAQ:RIGL) submits a New Drug Application
- to the FDA seeking approval of fostamatinib for the treatment of
patients with chronic and persistent immune thrombocytopenia (ITP), an Orphan Drug indication.
- Fostamatinib inhibits an enzyme called spleen tyrosine kinase (SYK) which plays a key role in certain blood cancers and autoimmune disorders.
(Vom Mitglied beendet)